Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Q1 2025 Earnings Presentation
24 slides from Oriola Corp Class B's earnings presentation, Apr 29, 2025
Slide 1: Interim Report January-March 2025
Interim Report January-March 2025 29 April 2025
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda 1 Q1 2025 highlights 2 Operating environment 3 Segments 4 Financial review Q&A Q1 2025 29 APRIL 2025 3
Slide 4: Steady growth and progress towards long-term goals
Steady growth and progress towards long-term goals • Good sales growth supported by both segments. • Sales margin improved supported by Distribution segment. Q1 25 • Adjusted EBITDA declined due to higher costs. Net sales • Good progress towards long-term goals – customer satisfaction at 447 (375) +
Slide 5: Operating environment
Operating environment • Consumer confidence weak – in Finland clearly below long-term average, in Sweden signalling subdued sentiment. • Cost inflation has slowed down, with more normalised energy and fuel prices. • The challenges in the availability of pharmaceuticals continues in Europe. • Value o
Slide 6: Q1: Distribution segment
Q1: Distribution segment • Net sales grew 22% to EUR 359 • Strategic focus to enhance customer (294) million. centricity to build strong partnerships • Solid volumes in Sweden, weak • High quality of services supporting market in Finland impacted sales. customer satisfaction • Change from consignmen
Slide 7: Q1: Wholesale segment
Q1: Wholesale segment • Net sales grew 9% to EUR 88 (81) • Long-term strategic goal to grow million. wholesale business. • Growth in Sweden, sales in Finland • Portfolio expansion and collaboration impacted by weak market and strikes with e-com customers across in retail channel. markets. • Profitab
Slide 8: Financial review
Financial review Q1 2025 29 APRIL 2025 8
Slide 9: Changes in financial reporting as of 1 Jan 2025
Changes in financial reporting as of 1 Jan 2025 • Reporting segments remain unchanged: Distribution and Wholesale • New key financial indicators introduced • Sales margin = Net sales – material purchases and exchange rate differences on sales and purchases • EBITDA = Earnings before interest, taxes,
Slide 10: Q1: Invoicing and net sales
Q1: Invoicing and net sales Invoicing and net sales EUR million 1,000 Invoicing • Invoicing grew 10% to EUR 1,000.2 (908.4) million 908 +10% • Net sales grew 19% EUR 447.1 (375.1) million • Organic growth 8.1% • Customer changing from consignment stock to Oriola’s inventory in Q3 2024 impacting net
Slide 11: Q1: Sales margin and EBITDA
Q1: Sales margin and EBITDA Sales margin EUR million Adjusted EBITDA EUR million +4% 41 42 • Improvement in the • Decline mainly due to 40 40 7.7 7.5 Adj. EBITDA Wholesale segment. 38 Distribution segment driven by new customers and high -2% • Dose Sweden improving service sales. compared to last ye
Slide 12: Q1: Adjusted EBITDA
Q1: Adjusted EBITDA Adjusted EBITDA* by segment EUR million • Dose Sweden adjusted EBITDA +0.2 MEUR (-0.5 0.1 MEUR). 7.7 0.7 -1.2 7.5 0.2 • Distribution segment improvement mainly related to sales margin. • Wholesale adjusted EBITDA lower than last year. Q1 24 Dose Sweden Distribution Wholesale Grou
Slide 13: Q1: Distribution segment
Q1: Distribution segment Invoicing and net sales EUR million Adjusted EBITDA EUR million 912 Invoicing 827 • Solid volumes in Sweden, • Net sales growth and +10% weak market affected 7.1 favourable product mix. sales in Finland. 6.3 • Dose Sweden impacting • Net sales growth partly +13% positively.
Slide 14: Q1: Wholesale segment
Q1: Wholesale segment Net sales EUR million Adjusted EBITDA EUR million 88.1 • Growth in Swedish • Decline due to unfavourable 81.1 wholesale business product mix and higher +9% operating expenses • Finnish wholesale affected by a weak market, • Planned investments in customers stockpiling in 3.6 gr
Slide 15: Profit burdened by impairment and write-down
Profit burdened by impairment and write-down Net profit EUR million 6.0 1-3 2025 2025 • EBITDA below last year due to higher adjusting 1-3 -8.7 items. • Total adjusting items were MEUR -1.6 (-0.9) related -2.8 -1.6 to ERP MEUR -1.3 and sale of dose dispensing -1.0 0.0 business MEUR -0.3. -5.4 • Impa
Slide 16: Positive free cash flow
Positive free cash flow Free cash flow EUR million 1-3 2025 Q1 Q1 Abs. EUR million 2025 2024 change • EBITDA below last year due to higher adjusting items. EBITDA 6.0 6.7 -0.8 • Positive working capital development Adjustments 0.0 -0.2 0.1 • Taxes and investments at last year’s level. • Free cash fl
Slide 17: Net debt on a low level
Net debt on a low level Net interest-bearing debt EUR million Net interest-bearing debt items 19 31 Mar 31 Mar Abs. 9 EUR million 2025 2024 change -55.0 Bank loans (syndicated bank & term) 30.0 57.2 -27.2 -2 -9 -7 Commercial papers 17.9 24.5 -6.6 -12 -21 Advance payment from pharmacies 8.4 10.5 -2.1
Slide 18: Solid financial position
Solid financial position Gearing1 and equity ratio % Gearing Equity ratio 1-3 2025 23 • The impairment and 21 19 19 17 17 18 write-down in Dose 15 14 Sweden, adjusting 9 5 items (mainly ERP) and the negative result from -1 Kronans Apotek had a -6 -5 negative impact on the -8 -12 net result and the e
Slide 19: Kronans Apotek (Swedish Pharmacy Holding)
Kronans Apotek (Swedish Pharmacy Holding) 2025 2024 Change 2024 Key figures EUR million 1-3 1-3 % 1-12 Net sales 295.2 286.4 3.1 1,151.1 EBITA 0.9 -4.4 -5.9 EBITA % 0.3 -1.5 -0.5 Adjusted EBIT 0.2 -5.0 -8.0 Adjusted EBIT % 0.1 -1.7 -0.7 Net interest-bearing debt 84.7 94.7 -10.6 96.9 Q1 2025: Joint v
Slide 20: Combination of share classes
Combination of share classes The Annual General Meeting (2 April 2025) approved the shareholder's proposal to combine the company's A and B share classes without increasing the share capital so that after the combination of the share classes, the company will have only one single share class. The co
Slide 21: Outlook refined
Outlook refined In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of cert
Slide 22: Q1 25 Key takeaways
Q1 25 Key takeaways Steady progress towards long-term goals Good sales growth and sales margin Remain focused on executing refined strategy improvement and being cost conscious Q1 2025 29 APRIL 2025 22
Slide 23: Our next event
Our next event 18 July 2025 Q2 2025 Half-Year Report Thank you for joining us!
Slide 24: Health for life